{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T07:36:45Z","timestamp":1774251405330,"version":"3.50.1"},"reference-count":23,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Isavuconazole has high oral bioavailability and a predictable pharmacokinetic profile, and is a first-line agent for invasive fungal disease in adults. In children, its use is off-label. A 14-year-old boy received oral isavuconazole (200\u00a0mg daily) for pulmonary aspergillosis after allogeneic hematopoietic stem cell transplantation. After 2\u00a0months of therapy, the steady-state trough concentration increased from 2.2\u00a0mg\/L to 15.0\u00a0mg\/L, well above the suggested range (2.0\u20135.0\u00a0mg\/L). Pharmacogenetic analysis revealed a CYP3A5\u22173\/\u22173 (poor metabolizer) genotype. The drug accumulation likely reflected a combined effect of no CYP3A5 activity, long-term therapy, and possible competition within the CYP3A4 pathway from concomitant medications. It is still unclear whether these high levels cause toxic reactions. This case highlights the need for baseline and follow up steady-state therapeutic drug levels in pediatric patients receiving off-label isavuconazole, especially during extended therapy. Monitoring may help detect supratherapeutic exposure early and guide dose adjustments to optimize the therapeutic outcomes.<\/jats:p>","DOI":"10.3389\/fphar.2026.1807350","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:42:44Z","timestamp":1774248164000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Pediatric isavuconazole supratherapeutic exposure: a case of long-term use, CYP3A5 poor metabolizer genotype and concomitant CYP3A4 medications"],"prefix":"10.3389","volume":"17","author":[{"given":"Manman","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pharmacy Administration, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai JiaoTong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai JiaoTong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Zhou","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Center, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai JiaoTong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changying","family":"Luo","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Center, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai JiaoTong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaodong","family":"Wang","sequence":"additional","affiliation":[{"name":"Blood and Marrow Transplantation Center, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai JiaoTong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Administration, Shanghai Children\u2019s Medical Center, School of Medicine, Shanghai JiaoTong University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin. Pharmacokinet."},{"key":"B2","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1093\/mmy\/myaa022","article-title":"Lessons from isavuconazole therapeutic drug monitoring at a United Kingdom reference Center","volume":"58","author":"Borman","year":"2020","journal-title":"Med. Mycol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.3390\/pharmaceutics13122099","article-title":"Population pharmacokinetics and pharmacodynamic target Attainment of isavuconazole against Aspergillus fumigatus and Aspergillus flavus in adult patients with invasive fungal diseases: should therapeutic drug monitoring for isavuconazole be considered as mandatory as for the other mold-active azoles?","volume":"13","author":"Cojutti","year":"2021","journal-title":"Pharmaceutics"},{"key":"B4","doi-asserted-by":"publisher","first-page":"103247","DOI":"10.5500\/wjt.v15.i2.103247","article-title":"Predictive value of tacrolimus concentration\/dose ratio in first post-transplant week for CYP3A5-polymorphism in kidney-transplant recipients","volume":"15","author":"Dung","year":"2025","journal-title":"World J. Transpl."},{"key":"B5","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3390\/jof6040324","article-title":"Isavuconazole: mechanism of action, clinical efficacy, and resistance","volume":"6","author":"Ellsworth","year":"2020","journal-title":"J. Fungi (Basel)"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000547799","article-title":"Role of a therapeutic drug monitoring-guided strategy of isavuconazole for optimizing Efficacy\/Safety outcomes in onco-hematological pediatric patients: a systematic review","volume":"70","author":"Gatti","year":"2025","journal-title":"Chemotherapy"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1563566","DOI":"10.3389\/fphar.2025.1563566","article-title":"Correlation between UGT1A1 polymorphism and efficacy and toxicity of irinotecan in Chinese cancer patients","volume":"16","author":"Geng","year":"2025","journal-title":"Front. Pharmacol."},{"key":"B8","volume-title":"The sanford guide to antimicrobial therapy","author":"Gilbert","year":"2025"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(20)30723-3","article-title":"8th European Conference on Infections in Leukaemia: 2020 guidelines for the diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or post-haematopoietic cell transplantation","volume":"22","author":"Groll","year":"2021","journal-title":"Lancet Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1093\/ehjcvp\/pvad070","article-title":"Impact of P-glycoprotein and CYP3A4-interacting drugs on clinical outcomes in patients with atrial fibrillation using non-vitamin K antagonist oral anticoagulants: a nationwide cohort study","volume":"9","author":"Grymonprez","year":"2023","journal-title":"Eur. Heart J. Cardiovasc Pharmacother."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1093\/jac\/dkaf128","article-title":"Isavuconazole therapeutic drug monitoring and association with adverse events","volume":"80","author":"Huang","year":"2025","journal-title":"J. Antimicrob. Chemother."},{"key":"B12","doi-asserted-by":"publisher","first-page":"760","DOI":"10.1016\/S0140-6736(15)01159-9","article-title":"Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by aspergillus and other filamentous fungi (SECURE): a phase3, randomised-controlled, non-inferiority trial","volume":"387","author":"Maertens","year":"2016","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/myc.12831","article-title":"Treatment outcomes in patients with proven\/probable vs possible invasive mould disease in a phase III trial comparing isavuconazole vs voriconazole","volume":"61","author":"Maertens","year":"2018","journal-title":"Mycoses"},{"key":"B14","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(16)00071-2","article-title":"Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis","volume":"16","author":"Marty","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"B15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","article-title":"Executive summary: practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"B16","doi-asserted-by":"publisher","first-page":"100736","DOI":"10.1016\/j.mmcr.2025.100736","article-title":"Isavuconazole: need for therapeutic drug monitoring and CYP polymorphism testing","volume":"50","author":"Soman","year":"2025","journal-title":"Med. Mycol. Case Rep."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e16113","DOI":"10.1097\/MD.0000000000016113","article-title":"Correlation between gene polymorphism and blood concentration of calcineurin inhibitors in renal transplant recipients: an overview of systematic reviews","volume":"98","author":"Su","year":"2019","journal-title":"Med. Baltim."},{"key":"B18","doi-asserted-by":"publisher","first-page":"107619","DOI":"10.1016\/j.ijantimicag.2025.107619","article-title":"Therapeutic drug monitoring of isavuconazole: trends and update","volume":"66","author":"Tan","year":"2025","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B19","doi-asserted-by":"publisher","first-page":"433","DOI":"10.3324\/haematol.2016.152900","article-title":"ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients","volume":"102","author":"Tissot","year":"2017","journal-title":"Haematologica"},{"key":"B20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/cpdd.285","article-title":"Pharmacokinetic evaluation of CYP3A4-mediated drug-drug interactions of isavuconazole with rifampin, ketoconazole, midazolam, and ethinyl estradiol\/norethindrone in healthy adults","volume":"6","author":"Townsend","year":"2017","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1111\/myc.13300","article-title":"Concomitant use of isavuconazole and CYP3A4\/5 inducers: where pharmacogenetics meets pharmacokinetics","volume":"64","author":"Van Daele","year":"2021","journal-title":"Mycoses"},{"key":"B22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/03602530902843483","article-title":"Polymorphism of human cytochrome P450 enzymes and its clinical impact","volume":"41","author":"Zhou","year":"2009","journal-title":"Drug Metab. Rev."},{"key":"B23","doi-asserted-by":"publisher","first-page":"891336","DOI":"10.3389\/fphar.2022.891336","article-title":"Antifungal drugs and drug-induced liver injury: a real-world Study leveraging the FDA adverse event reporting System database","volume":"13","author":"Zhou","year":"2022","journal-title":"Front. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1807350\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T06:42:51Z","timestamp":1774248171000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2026.1807350\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":23,"alternative-id":["10.3389\/fphar.2026.1807350"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2026.1807350","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]},"article-number":"1807350"}}